Defense World
22 Nov 2025, 08:45 UTC · 43w ago
Verdict
Headline takes no side. We score AURA +0.50 across three claims — strongly bullish.
+0.50strongly bullish
More positive than 69% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Aura Biosciences holds a consensus Wall Street rating of 'Moderate Buy'.
So whatA moderate buy consensus provides a modestly positive signal for the stock, but is largely priced in and lacks the force of a strong consensus upgrade.
More positive than 52% of claims this week
Three out of six covering analysts rate Aura Biosciences as a buy.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 46% of claims this week
One out of six covering analysts rates Aura Biosciences as a sell.
More negative than 64% of claims this week
Which stocks this story touches
More positive than 69% of ticker scores this week
The company has received a consensus rating of 'Moderate Buy' from analysts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
1d ago
+13.1%
Price agrees with the score
$6.15 vs $5.44 close before publication (Nov 21) · not market-adjusted
AURA chart →
